Director Paul A. Ainsworth be a panelist at the Summit on Biosimilars on June 24, 2019, in New York, New York. He will be speaking on the panel, "The ITC: Examining the Role of this Alternate Forum in Biosimilars Disputes."
About the panel:
- Exploring the ITC as a venue for reaching a relatively swifter and earlier resolution of a biosimilars challenge
- Weighing the pros and cons of avoiding the patent dance and assessing the benefits of asserting any number of claims in lieu of the aBLA process
- Capitalizing on the benefit of receiving remedies beyond the restrictions imposed by the district courts